Skip to main content
    L

    Lexaria Bioscience Corp (LEXX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.18
    -0.23 (-5.22%)

    Market Cap: $9.35M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Lexaria Bioscience Corp (LEXX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Lexaria Bioscience (LEXX) has a market cap of $9.35M. It kept -3985.58% of revenue as net income over the last 12 months. Its share count is up 35.56% from a year earlier.

    Total Valuation

    Market Cap$9.35M
    Latest price (Nov 17, 2026)$4.18

    Key Dates

    The next earnings report is expected on Nov 26, 2026, covering the quarter ending Aug 31, 2026.

    Next Earnings DateNov 26, 2026 (expected)
    Last Earnings DateJul 13, 2026
    Fiscal Year EndAugust

    Share Statistics

    The share count rose 1.48% in the quarter ended May 31, 2026 and grew 33.80% a year over 2 years.

    Shares Outstanding1.65M
    Shares Change (YoY)+35.56%
    Shares Change (QoQ)+1.48%
    Share Count Growth (2Y CAGR)+33.80%

    Valuation Ratios

    Sales and book value multiples are 12.8x and 1.5x.

    P/S Ratio12.8x
    Forward P/S6.7x
    P/B Ratio1.5x
    P/TBV Ratio1.6x

    Price Statistics

    The stock is down 73.71% over 52 weeks and trades 18.75% above its 50-day average.

    Beta (1Y)0.80
    52-Week Change-73.71%
    1-Month Change+60.77%
    3-Month Change-63.68%
    6-Month Change-51.73%
    5-Year Change-96.24%
    Total Return (1Y)-73.71%
    Total Return (3Y CAGR)-40.30%
    Total Return (5Y CAGR)-45.44%
    Return vs SPY (1Y)-85.02%
    Max Drawdown (1Y)-87.06%
    Max Drawdown (3Y)-97.23%
    Sharpe Ratio (1Y)-0.98
    Correlation with SPY (1Y)0.08
    50-Day Average$3.52
    200-Day Average$8.51
    52-Week Range$2.43 to $21.60
    RSI (14 Days)52.8
    Average Volume (20 Days)26.29K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 10.60x current liabilities.

    Current Ratio10.60x
    Quick Ratio10.60x

    Returns and Efficiency

    Return on equity is -163.18% and return on assets is -161.71% over the last 12 months.

    Return on Equity (ROE)-163.18%
    Return on Assets (ROA)-161.71%
    Return on Capital Employed (ROCE)-175.90%
    Asset Turnover0.03x
    Receivables Turnover11.91x

    Scores

    LEXX has an Altman Z-Score of -14.87, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-14.87
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $194.00K over the last 12 months is down 68.50% from the 12 months before.

    Revenue$194.00K
    Revenue Growth (YoY)-68.50%
    Gross Profit$169.80K
    Operating Income-$7.71M
    Pretax Income-$7.74M
    Net Income-$7.73M
    EBITDA-$7.66M
    EBIT-$7.74M
    Reported EPS (TTM)-$5.25

    Trailing 12 months through May 31, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 99.16% of the $4.78M in total assets.

    Cash and Equivalents$3.48M
    Working Capital$3.68M
    Shareholder Equity$4.74M
    Book Value Per Share$2.87
    Tangible Book Value$4.40M
    Tangible Book Per Share$2.66
    Total Assets$4.78M
    Total Liabilities$437.09K

    Balance sheet as of May 31, 2026.

    Full balance sheet

    Cash Flow

    After $101.87K of capital spending, operating cash flow left -$7.53M of free cash flow.

    Operating Cash Flow-$7.43M
    Capital Expenditures$101.87K
    Free Cash Flow-$7.53M
    FCF Per Share-$3.57
    Depreciation and Amortization$76.57K

    Trailing 12 months through May 31, 2026.

    Full cash flow statement

    Margins

    The operating margin is -3973.16%.

    Gross Margin87.53%
    Operating Margin-3973.16%
    Pretax Margin-3987.65%
    Net Margin-3985.58%
    EBITDA Margin-3948.18%
    EBIT Margin-3987.65%
    FCF Margin-3880.08%
    Gross Margin (5Y Average)86.45%

    Growth

    Revenue grew 40.34% a year over 3 years.

    Revenue Growth (3Y CAGR)+40.34%
    Revenue Growth (5Y CAGR)+12.92%
    Book Value Per Share Growth (2Y CAGR)-42.37%
    Tangible Book Per Share Growth (2Y CAGR)-40.73%

    Revenue and profit by year

    Dividends and Yields

    LEXX does not pay a dividend. Its free cash flow yield is -108.89%.

    FCF Yield-108.89%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-15 reverse split on Aug 3, 2026.

    Last Split DateAug 3, 2026
    Split TypeReverse split
    Split Ratio1:15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About LEXX

    What is LEXX's market cap?

    Lexaria Bioscience has a market cap of $9.35M.

    How many shares of LEXX are outstanding?

    Lexaria Bioscience has 1.65M shares outstanding. The count is up 35.56% from a year earlier.

    Does LEXX pay a dividend?

    No. Lexaria Bioscience does not pay a dividend.